AGIOS PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AGIOS PHARMACEUTICALS, INC. | ||
| February 12, 2026 | By: | /s/ Brian Goff |
|---|---|---|
| Brian GoffChief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Brian Goff | Chief Executive Officer(Principal executive officer) | February 12, 2026 |
| Brian Goff | ||
| /s/ Cecilia Jones | Chief Financial Officer(Principal financial officer) | February 12, 2026 |
| Cecilia Jones | ||
| /s/ T.J. Washburn | Vice President, Controller(Principal accounting officer) | February 12, 2026 |
| T.J. Washburn | ||
| /s/ Jacqualyn A. Fouse | Chair of the Board of Directors | February 12, 2026 |
| Jacqualyn A. Fouse, Ph.D. | ||
| /s/ Jay Backstrom | Director | February 12, 2026 |
| Jay Backstrom, M.D., M.P.H. | ||
| /s/ Rahul Ballal | Director | February 12, 2026 |
| Rahul Ballal, Ph.D. | ||
| /s/ Jeffrey Capello | Director | February 12, 2026 |
| Jeffrey Capello | ||
| /s/ Kaye Foster | Director | February 12, 2026 |
| Kaye Foster | ||
| /s/ Maykin Ho | Director | February 12, 2026 |
| Maykin Ho, Ph.D. | ||
| /s/ Catherine Owen Adams | Director | February 12, 2026 |
| Catherine Owen Adams | ||
| /s/ David Scadden | Director | February 12, 2026 |
| David Scadden, M.D. | ||
| /s/ Cynthia Smith | Director | February 12, 2026 |
| Cynthia Smith | ||
Index to Consolidated Financial Statements
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Comprehensive (Loss) Income | F-6 |
| Consolidated Statements of Stockholders’ Equity | F-7 |
| Consolidated Statements of Cash Flows | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.